Drug interaction profile of the HIV integrase inhibitor cabotegravir: Assessment from in vitro studies and a clinical investigation with midazolam

Xenobiotica

Volumn 46, Issue 5, 2016, Pages 445-456

  Reese, Melinda J ^a   Bowers, Gary D ^a   Humphreys, Joan E ^a   Gould, Elizabeth P ^a   Ford, Susan L ^a   Webster, Lindsey O ^a   Polli, Joseph W ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

BCRP; Cytochrome P450; drug metabolism; infections disease; OAT; P glycoprotein; transporters

Indexed keywords

BILE SALT EXPORT PUMP; CABOTEGRAVIR; MESSENGER RNA; MIDAZOLAM; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; ABC TRANSPORTER; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CYTOCHROME P450 3A; INTEGRASE INHIBITOR; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 3; PYRIDONE DERIVATIVE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; MDCK CELL LINE; MEMBRANE VESICLE; NONHUMAN; ADOLESCENT; ADULT; AGED; ANIMAL; ANTAGONISTS AND INHIBITORS; AREA UNDER THE CURVE; CHEMISTRY; CLINICAL TRIAL; DOG; DOSE RESPONSE; DRUG EFFECTS; DRUG INTERACTION; FEMALE; HIV INFECTIONS; IC50; MALE; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANIMALS; ANTI-HIV AGENTS; AREA UNDER CURVE; ATP-BINDING CASSETTE TRANSPORTERS; CYTOCHROME P-450 CYP3A; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HEPATOCYTES; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; MADIN DARBY CANINE KIDNEY CELLS; MALE; MIDAZOLAM; MIDDLE AGED; ORGANIC ANION TRANSPORT PROTEIN 1; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; PYRIDONES; YOUNG ADULT;

EID: 84958121340     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2015.1081993     Document Type: Article

References (54)

1. Aherne GW, Piall E, Marks V, et al. (1978). Prolongation and enhancement of serum methotrexate concentrations by probenecid. Br Med J 1: 1097-9
2. Annaert P, Ye Z W, Stieger B, et al. (2010). Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica 40: 163-76
3. Benet LZ, Amidon GL, Barends DM, et al. (2008). The use of BDDCS in classifying the permeability of marketed drugs. Pharm Res 25: 483-8
4. Benet LZ, Broccatelli F, Oprea TI. (2011). BDDCS applied to over 900 drugs. AAPS J 13: 519-47
5. Bowers GD, Culp A, Reese M, et al. (2015). Disposition and metabolism of cabotegravir: similarities in biotransformation and excretion between different species and routes of administration. Xenobiotica Early Online DOI 10.3109/00498254.2015.1060372
6. Busti AJ, Bain AM, Hall RG, et al. (2008). Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. J Cardiovasc Pharmacol 51: 605-10
7. Chen M, Nafziger AN, Bertino JS Jr. (2006). Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam. Drug Metab Dispos 34: 2079-82
8. Cheng Y, Prusoff WH. (1973). Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-108
9. Cihlar T, Ray A S, Laflamme G, et al. (2007). Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors. Antivir Ther 12: 267-72
10. Eagling VA, Back DJ, Barry MG. (1997). Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 44: 190-4
11. European medicines agency. Guide on the investigation of drug interactions. (2012). Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/07/WC500129606.pdf [last accessed 24 Aug 2015]
12. Evans DF, Pye G, Bramley R, et al. (1988). Measurement of gastrointestinal PH profiles in normal ambulant human subjects. Gut 29: 1035-41
13. Fahmi OA, Hurst S, Plowchalk D, et al. (2009). Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction. Drug Metab Dispos 37: 1658-66
14. Food and drug administration (FDA). Guidance for industry drug interaction studies-Study design, data analysis, implications for dosing and labeling recommendations. 2012. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm292362.pdf [last accessed 24 Aug 2015]
15. Ford SL, Gould E, Chen S, et al. (2013). Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744. Antimicrob Agents Chemother 57: 5472-7
16. Generaux GT, Bonomo FM, Johnson M, et al. (2011). Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins. Xenobiotica 41: 639-51
17. Giacomini KM, Huang SM, Tweedie DJ, et al. (2010). Membrane transporters in drug development. Nat Rev Drug Discov 9: 215-36
18. Hall AM, Hendry BM, Nitsch D, et al. (2011). Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis 57: 773-80
19. Imamura Y, Murayama N, Okudaira N, et al. (2011). Prediction of fluoroquinolone-induced elevation in serum creatinine levels: a case of drug-endogenous substance interaction involving the inhibition of renal secretion. Clin Pharmacol Ther 89: 81-8
20. Imaoka T, Kusuhara H, Adachi M, et al. (2007). Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol 71: 619-27
21. Ito K, Chiba K, Horikawa M, et al. (2002). Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data? AAPS PharmSci 4: E25
22. Izzedine H, Thibault V, Valantin MA, et al. (2010). Tenofovir/probenecid combination in HIV/HBV-coinfected patients: How to escape Fanconi syndrome recurrence? AIDS 24: 1078-9
23. Kearney BP, Mathias A, Mittan A, et al. (2006). Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr 43: 278-83
24. Kiser JJ, Gerber JG, Predhomme JA, et al. (2008). Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr 47: 570-8
25. Kivisto KT, Niemi M, Fromm MF. (2004). Functional interaction of intestinal CYP3A4 and P-glycoprotein. Fundam Clin Pharmacol 18: 621-6
26. Koteff J, Borland J, Chen S, et al. (2013). A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. Br J Clin Pharmacol 75: 990-6
27. Lawrence SK, Nguyen D, Bowen C, et al. (2014). The metabolic drug-drug interaction profile of dabrafenib: in vitro investigations and quantitative extrapolation of the P450-mediated DDI risk. Drug Metab Dispos 42: 1180-90
28. Lepist EI, Zhang X, Hao J, et al. (2014). Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat. Kidney Int 86: 350-7
29. Lui CY, Amidon GL, Berardi RR, et al. (1986). Comparison of gastrointestinal PH in dogs and humans: implications on the use of the beagle dog as a model for oral absorption in humans. J Pharm Sci 75: 271-4
30. Madan A, Graham RA, Carroll KM, et al. (2003). Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 31: 421-31
31. Margolis D, Bhatti L, Smith G, et al. (2013). Once-daily oral GSK1265744 (GSK744) as part of combination therapy in antiretroviral naive adults: 24-week safety and efficacy results from LATTE study (LAI116482). 14th European AIDS Conference
32. Min S, Song I, Borland J, et al. (2010). Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 54: 254-8
33. Mukwaya G, MacGregor T, Hoelscher D, et al. (2005). Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers. Antimicrob Agents Chemother 49: 4903-10
34. Obach RS, Walsky RL, Venkatakrishnan K. (2007). Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 35: 246-55
35. Obach RS, Walsky RL, Venkatakrishnan K, et al. (2006). The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316: 336-48
36. Polli JW, Humphreys J E, Harmon KA, et al. (2008). The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos 36: 695-701
37. Polli JW, Wring SA, Humphreys JE, et al. (2001). Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299: 620-8
38. Rautio J, Humphreys JE, Webster LO, et al. (2006). In vitro P-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos 34: 786-92
39. Ray AS, Cihlar T, Robinson KL, et al. (2006). Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 50: 3297-304
40. Reese MJ, Savina PM, Generaux GT, et al. (2013). In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos 41: 353-61
41. Rostami-Hodjegan A, Tucker G. (2004). In Silico' simulations to assess the in vivo' consequences of in vitro' metabolic drug-drug interactions. Drug Discov Today Technol 1: 441-8
42. Sekar VJ, Spinosa-Gurzman S, Marien K, et al. Pharmacokinetic drug-drug interaction between new HIV protease inhibitior darunavir (TMC114) and the lipid-lowering agent pravastatin. 8th international workshop on pharmacology of HIV therapy. 2007
43. Sekhar RV, Balasubramanyam A. (2010). Treatment of dyslipidemia in HIV-infected patients. Expert Opin Pharmacother 11: 1845-54
44. Shardlow CE, Generaux GT, MacLauchlin CC, et al. (2011). Utilizing drug-drug interaction prediction tools during drug development: enhanced decision making based on clinical risk. Drug Metab Dispos 39: 2076-84
45. Song I, Min SS, Borland J, et al. (2011). The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants. J Clin Pharmacol 51: 237-42
46. Spreen W, Ford SL, Chen S, et al. (2014a). GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects. J Acquir Immune Defic Syndr 67: 481-6
47. Spreen W, Min S, Ford SL, et al. (2013a). Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor. HIV Clin Trials 14: 192-203
48. Spreen W, Williams P, Margolis D, et al. (2014b). Pharmacokinetics, safety, and tolerability with repeat doses of gSK1265744 and rilpivirine (TMC278) Long-Acting Nanosuspensions in Healthy Adults. J Acquir Immune Defic Syndr 67: 487-92
49. Spreen WR, Margolis DA, Pottage JC, Jr. (2013b). Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr Opin HIV AIDS 8: 565-71
50. Stray KM, Bam RA, Birkus G, et al. (2013). Evaluation of the effect of cobicistat on the in vitro renal transport and cytotoxicity potential of tenofovir. Antimicrob Agents Chemother 57: 4982-9
51. Tanihara Y, Masuda S, Sato T, et al. (2007). Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol 74: 359-71
52. Urakami Y, Kimura N, Okuda M, et al. (2004). Creatinine transport by basolateral organic cation transporter HOCT2 in the human kidney. Pharm Res 21: 976-81
53. Weiss J, Haefeli WE. (2013). Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro. Int J Antimicrob Agents 41: 484-7
54. Weiss J, Rose J, Storch CH, et al. (2007). Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother 59: 238-45